No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Nova Biomedical Adds PT/INR Test to Allegro® Analyzer

Editor: What To Know

  • Now with the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro, and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the point-of-care.
  • All Allegro tests use easy capillary fingerstick sampling, eliminating the need for venipunctures or a trained phlebotomist, and easy-to-use disposable test cartridges or strips.
  • Allegro's quick six to nine-minute cartridge test times and the ability to measure two cartridges simultaneously provide rapid results immediately to the physician.

Nova Biomedical has announced the addition of PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. Now with the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro, and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the point-of-care. The Allegro analyzer and this new PT/INR test are available now for purchase in CE regulated countries.

This upgrade allows Allegro to monitor patient coagulation therapy in addition to testing for glycemic control, kidney function, anemia, gout, and cardiac risk with a full lipids panel. PT/INR is just one of 18 tests for the Allegro platform, including HbA1c, Cholesterol, Triglycerides, Glucose, Creatinine, UACR, Hemoglobin, Hematocrit, and Uric Acid.

Allegro is a compact, fast, and simple POC analyzer that features a clinically important menu of twelve measured and individually selectable tests, plus six calculated tests. All Allegro tests use easy capillary fingerstick sampling, eliminating the need for venipunctures or a trained phlebotomist, and easy-to-use disposable test cartridges or strips. Allegro’s quick six to nine-minute cartridge test times and the ability to measure two cartridges simultaneously provide rapid results immediately to the physician.

Allegro is ideal for primary care settings with tests that are easily performed by non-technical personnel and feature disposable, ready-to-use cartridges and test strips. All results are ready during the patient visit, simplifying clinic workflow and producing cost savings for providers while offering clinical benefits for patients.

Allegro is the only analyzer that can measure HbAlc, lipids, glucose, and creatinine from a capillary sample. Its innovative design comprises dual measurement bays, which offers the unique ability to measure two cartridges simultaneously, doubling throughput and improving efficiency.

Allegro’s companion meters wirelessly transmit results to the analyzer, where they combine with all cartridge test results for one patient report. All results can be transmitted to electronic medical records for providers to review with patients during the visit. Having immediate results during the patient visit reduces clinic follow-up calls, letters, and patient re-visits, and improves patient satisfaction, compliance with care plans, and outcomes.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy